What question did this study set out to answer?

The aim is to address the lack of evidence supporting pharmacotherapy in GOLD Stage 1 COPD.

April 25, 2026

GOLD Stage 1 COPD pharmacotherapy: big question, few answers

Key Points

The aim is to address the lack of evidence supporting pharmacotherapy in GOLD Stage 1 COPD.
Review of current literature and clinical guidelines regarding GOLD Stage 1 COPD.
Assessment of the prevalence of COPD in the global population.
Identification of gaps in randomized controlled trials for Stage 1 COPD treatment.
Approximately 50% of the 200–400 million individuals with COPD are classified as GOLD Stage 1.
No robust randomized controlled trials currently support routine pharmacotherapy for this population.
Calls for more comprehensive studies to evaluate treatment efficacy in Stage 1 COPD.

Abstract

Shareable abstract Despite GOLD 1 accounting for roughly half of the 200–400 million people with COPD worldwide, randomised controlled trials supporting the routine use of pharmacotherapy in this group are lacking. Better, more considered studies are sorely needed.

Ask AI

Helpful

Bookmark

View Full Paper